Research Feed

Regeneron reported Q4 2025 earnings last week. Stock down 1.1% on the day, up 2.1% since. Market yawned. That reaction tells you something: The Street is focused on the known franchises (Dupixent +36% YoY, Eylea HD mix shift progressing as expected). They're missing three pipeline programs where the